Recombinant human erythropoietin in the treatment of cisplatin-based-chemotherapy-induced a-nemia / 中国癌症杂志
China Oncology
; (12)2001.
Article
Dans Zh
| WPRIM
| ID: wpr-675127
Responsable en Bibliothèque :
WPRO
ABSTRACT
Purpose:To study the efficiency and the safety of recombinant human erythropoietin (rHuEPO) in the treatment of chemotherapy-induced anemia.Methods:41 tumor patients were randomized into two groups:EPO-treatment group and control group,in order to observe the changes of the haemoglobin level,transfusion requirement and quality of life for the two groups respectively.Results:①the increase of haemoglobin level and the quality of life in the EPO-treat- ment group compared with that in the control group was statistically significant.②the reduction of transfusion requirement in the EPO-treatment group compared with that in the control group was not statistically significant.③treatment of EPO has few side-effects and a good tolerance.Conclusions:rHuEPO in the treatment of chemotherapy-induced anemia is effec- tive and safe.Not only can it increase the haemoglobin level but also improve the quality of life for the patients,so it should be used widely.
Texte intégral:
1
Indice:
WPRIM
Type d'étude:
Clinical_trials
langue:
Zh
Texte intégral:
China Oncology
Année:
2001
Type:
Article